B. Riley keeps a Buy rating on Ovid Therapeutics (OVID) with a $3 price target following a transfer of coverage. The firm views OV329 as a “best-in-class contender” that could increase investor optimism.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Ovid Therapeutics management to meet with B. Riley
- Ovid Therapeutics Approves Key Proposals at Annual Meeting
- Ovid Therapeutics Sells Ganaxolone Royalties to Immedica
- Ovid enters agreement with Immedica for sale of future ganaxolone royalties
- Ovid Therapeutics: Promising Buy Opportunity with OV329 Advancements in Drug-Resistant Epilepsy